Xiangmei Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xiangmei Kong has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Huan Xu
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China
13 shared publicationsQilian Sheng
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China; NHC Key Laboratory of Myopia and Related Eye Diseases, Key Laboratory of Myopia and Related Eye Diseases, Chinese Academy of Medical Sciences, Shanghai, 200031, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, 200031, China
13 shared publicationsXinghuai Sun
Department of Ophthalmology & Visual Science, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China
12 shared publicationsXintong Fan
Eye Institute, Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China
11 shared publicationsRuyi Zhai
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, National Health Commission Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, People’s Republic of China
10 shared publications- Ruyi Zhai
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China
10 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1)
Association between capsulectomy shunt revision and Ahmed glaucoma valve implant exposure——Shanghai Ahmed glaucoma valve implant exposure (AGVIE) study
The Ahmed Glaucoma Valve (AGV) is a drainage device commonly used in the treatment of refractory glaucoma. Implant exposure is a major cause of surgical fa
- 22 June 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1)
Open AccessAssociation between capsulectomy shunt revision and Ahmed glaucoma valve implant exposure——Shanghai Ahmed glaucoma valve implant exposure (AGVIE) study
The Ahmed Glaucoma Valve (AGV) is a drainage device commonly used in the treatment of refractory glaucoma. Implant exposure is a major cause of surgical fa
- 8 January 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 264 (4) , 1079-1088
Long-term optic nerve head microvascular impairment after acute primary angle closure: an OCTA study
Purpose While previous studies documented transient reductions in fundus vessel density (VD) following acute primary angle closure (APAC), we investigated whether optic nerve head (ONH) and macular VD was lower long-term following APAC. The study aimed to describe long-term microvascular patterns after APAC and identify anatomical regions showing lower VD. Methods Resolved APAC, primary angle closure suspects (PACS), and age-sex-matched healthy controls were enrolled. Quantitative microvascular assessment was performed using spectral domain optical coherence tomography angiography (OCTA) system (RTvue XR Avanti; Optovue, Fremont, CA, USA), with 4.5*4.5 mm ONH and 3.0*3.0 mm macular scan protocols. Peripapillary VD was analyzed as the primary endpoint, while sectoral ONH VD and macular VD were evaluated as secondary measures. Results The median and range of interval between APAC onset and examination was 15, (1, 60) months. APAC eyes demonstrated marked reduction in peripapillary VD compared with PACS and controls. Macular VD was less affected. ONH VD positively correlated with structural parameters in APAC eyes. Conclusion Despite clinical resolution of APAC, peripapillary VD was lower in eyes with previous APAC compared with PACS and controls.
- 8 January 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 264 (4) , 1079-1088
Long-term optic nerve head microvascular impairment after acute primary angle closure: an OCTA study
Purpose While previous studies documented transient reductions in fundus vessel density (VD) following acute primary angle closure (APAC), we investigated whether optic nerve head (ONH) and macular VD was lower long-term following APAC. The study aimed to describe long-term microvascular patterns after APAC and identify anatomical regions showing lower VD. Methods Resolved APAC, primary angle closure suspects (PACS), and age-sex-matched healthy controls were enrolled. Quantitative microvascular assessment was performed using spectral domain optical coherence tomography angiography (OCTA) system (RTvue XR Avanti; Optovue, Fremont, CA, USA), with 4.5*4.5 mm ONH and 3.0*3.0 mm macular scan protocols. Peripapillary VD was analyzed as the primary endpoint, while sectoral ONH VD and macular VD were evaluated as secondary measures. Results The median and range of interval between APAC onset and examination was 15, (1, 60) months. APAC eyes demonstrated marked reduction in peripapillary VD compared with PACS and controls. Macular VD was less affected. ONH VD positively correlated with structural parameters in APAC eyes. Conclusion Despite clinical resolution of APAC, peripapillary VD was lower in eyes with previous APAC compared with PACS and controls.
- Open Access
- 1 September 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 11881-11894
Exosomal miR-450b-5p Secreted from Exendin-4-Stimulated Endothelial Cells Protects Retinal Ganglion Cells Against Ischemia Reperfusion Injury
Background: Retinal ischemia-reperfusion (RIR) injury represents a critical pathophysiological mechanism underlying various ocular ischemic diseases, characterized by progressive loss of retinal ganglion cells (RGCs). Exendin-4 (Ex-4), a widely used glucagon-like peptide-1 receptor (GLP-1R) agonist drug in the treatment of type 2 diabetes mellitus, has been reported to protect against ischemia-reperfusion (IR) injury in various vital organs. However, the potential neuroprotective effect of Ex-4 under RIR injury has been poorly understood. Methods: Immunofluorescence staining assay, hematoxylin and eosin (HE) staining were conducted to evaluate the neuroprotective role of Ex-4. A co-culture assay of human retinal vascular endothelial cells (HRVECs) and RGCs was established. Extracellular vesicles (EVs) were isolated from the culture supernatant of HRVECs with (E-EVs) or without Ex-4 treatment (O-EVs) under oxygen-glucose deprivation/reoxygenation (OGD/R) condition. Transmission electron microscopy (TEM), Nanoparticle tracking analysis (NTA) and Nano-flow cytometry (NanoFCM) were used to detect the presence and purity of EVs. Cell activity, reactive oxygen species (ROS) level, and cell death rate of RGCs were evaluated. Further global miRNA sequencing was performed on E-EVs or O-EVs to explore potential mechanisms. Results: Our findings revealed that Ex-4 had a GLP-1R-dependent neuroprotective effect on RGCs. Vascular endothelial cells (VECs) -derived EVs mediate the protective effect of Ex-4 on RGCs under acute RIR injury. We identified miR-450b-5p as a highly enriched miRNA in E-EVs. Treatment with either E-EVs or miR-450b-5p mimics significantly protected RGCs against RIR-induced injury. Mechanistic investigations identified acyl-coenzyme A (CoA) synthetase long-chain family member 4 (ACSL4) as a direct target of miR-450b-5p. Conclusion: Ex-4 exerts its neuroprotective effects under RIR injury by stimulating retinal VECs to secrete miR-450b-5p-enriched EVs, thereby revealing a novel endothelial-mediated neuroprotective pathway in ischemia diseases.
- 1 September 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 11881-11894
Open AccessExosomal miR-450b-5p Secreted from Exendin-4-Stimulated Endothelial Cells Protects Retinal Ganglion Cells Against Ischemia Reperfusion Injury
Background: Retinal ischemia-reperfusion (RIR) injury represents a critical pathophysiological mechanism underlying various ocular ischemic diseases, characterized by progressive loss of retinal ganglion cells (RGCs). Exendin-4 (Ex-4), a widely used glucagon-like peptide-1 receptor (GLP-1R) agonist drug in the treatment of type 2 diabetes mellitus, has been reported to protect against ischemia-reperfusion (IR) injury in various vital organs. However, the potential neuroprotective effect of Ex-4 under RIR injury has been poorly understood. Methods: Immunofluorescence staining assay, hematoxylin and eosin (HE) staining were conducted to evaluate the neuroprotective role of Ex-4. A co-culture assay of human retinal vascular endothelial cells (HRVECs) and RGCs was established. Extracellular vesicles (EVs) were isolated from the culture supernatant of HRVECs with (E-EVs) or without Ex-4 treatment (O-EVs) under oxygen-glucose deprivation/reoxygenation (OGD/R) condition. Transmission electron microscopy (TEM), Nanoparticle tracking analysis (NTA) and Nano-flow cytometry (NanoFCM) were used to detect the presence and purity of EVs. Cell activity, reactive oxygen species (ROS) level, and cell death rate of RGCs were evaluated. Further global miRNA sequencing was performed on E-EVs or O-EVs to explore potential mechanisms. Results: Our findings revealed that Ex-4 had a GLP-1R-dependent neuroprotective effect on RGCs. Vascular endothelial cells (VECs) -derived EVs mediate the protective effect of Ex-4 on RGCs under acute RIR injury. We identified miR-450b-5p as a highly enriched miRNA in E-EVs. Treatment with either E-EVs or miR-450b-5p mimics significantly protected RGCs against RIR-induced injury. Mechanistic investigations identified acyl-coenzyme A (CoA) synthetase long-chain family member 4 (ACSL4) as a direct target of miR-450b-5p. Conclusion: Ex-4 exerts its neuroprotective effects under RIR injury by stimulating retinal VECs to secrete miR-450b-5p-enriched EVs, thereby revealing a novel endothelial-mediated neuroprotective pathway in ischemia diseases.
- Open Access
- 18 July 2025
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 18 (7) , 1276-1281
Measurement of shallow anterior chamber depth using Lenstar and ultrasound biomicroscopy
AIM: To study the relationship between ultrasound biomicroscopy (UBM) and Lenstar when measuring anterior chamber depth (ACD) in eyes with shallow anterior chamber, and the necessity of conducting both examinations. METHODS: This is a retrospective observational study including 56 acute primary angle closure (APAC) eyes and 47 primary angle closure suspect (PACS) eyes with shallow ACD. ACD value measured by Lenstar and UBM were documented. The Bland-Altman plots were examined separately in all included eyes, APAC eyes and PACS eyes, for the assessment of agreement between two measurements. The agreement was compared across different population by evaluating mean difference, width of 95% limit of agreement (LoA) and the presence of proportional bias or outliers in Bland-Altman plots. RESULTS: The average ACD in APAC eyes (1.71±0.23 mm) was significantly smaller than that in PACS eyes (1.79±0.25 mm, P=0.038). Bland-Altman plots of both APAC eyes and PACS eyes showed small mean difference without the presence of proportional bias. However, compared with PACS eyes, the Bland-Altman plot of APAC eyes had wider 95% LoA and more outliers outside the 95% LoA. CONCLUSION: Despite the small ACD values, the two methods in measuring ACD, Lenstar and UBM, demonstrate substantial consistency when measuring PACS eyes. However, for the APAC population, the agreement might be limited, and thus the measured values should be interpreted with caution.
- 18 July 2025
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 18 (7) , 1276-1281
Open AccessMeasurement of shallow anterior chamber depth using Lenstar and ultrasound biomicroscopy
AIM: To study the relationship between ultrasound biomicroscopy (UBM) and Lenstar when measuring anterior chamber depth (ACD) in eyes with shallow anterior chamber, and the necessity of conducting both examinations. METHODS: This is a retrospective observational study including 56 acute primary angle closure (APAC) eyes and 47 primary angle closure suspect (PACS) eyes with shallow ACD. ACD value measured by Lenstar and UBM were documented. The Bland-Altman plots were examined separately in all included eyes, APAC eyes and PACS eyes, for the assessment of agreement between two measurements. The agreement was compared across different population by evaluating mean difference, width of 95% limit of agreement (LoA) and the presence of proportional bias or outliers in Bland-Altman plots. RESULTS: The average ACD in APAC eyes (1.71±0.23 mm) was significantly smaller than that in PACS eyes (1.79±0.25 mm, P=0.038). Bland-Altman plots of both APAC eyes and PACS eyes showed small mean difference without the presence of proportional bias. However, compared with PACS eyes, the Bland-Altman plot of APAC eyes had wider 95% LoA and more outliers outside the 95% LoA. CONCLUSION: Despite the small ACD values, the two methods in measuring ACD, Lenstar and UBM, demonstrate substantial consistency when measuring PACS eyes. However, for the APAC population, the agreement might be limited, and thus the measured values should be interpreted with caution.
- 14 August 2024
- Published by Taylor & Francis in Current Eye Research
- Vol. 49 (11) , 1180-1183
Expression of Matrix Metalloproteinase-3 in the Aqueous Humor of Patients with Posner-Schlossman Syndrome
Purpose To explore the expression of matrix metalloproteinase-3 (MMP-3) in the aqueous humor of patients with Posner-Schlossman syndrome (PSS), and the association between MMP-3 and PSS. Methods Peripheral blood and aqueous humor were routinely collected from 29 patients with PSS (PSS group) and 30 patients with age-related-cataract (ARC) (control group). The content of MMP-3 in serum and aqueous humor was measured by immunoturbidimetry. The correlation between MMP-3 and ophthalmic examination results were verified by Spearman's correlation analysis. Results The MMP-3 level in the aqueous humor of the PSS group was (25.86 +/- 13.4)ng/ml, significantly higher than that in the control group (3.9 +/- 2.7)ng/ml(p < 0.001), while there was no significant difference in serum MMP-3 level between the two groups (p = 0.125). The endothelial cell density (ECD) in the aqueous humor of the PSS group was (2078 +/- 440) cell/mm2, intraocular pressure (IOP) in the aqueous humor of the PSS group was (33 +/- 12) mmHg. The correlation analysis of aqueous humor MMP-3 and various ophthalmic examination results showed that aqueous humor MMP-3 had a moderate correlation with IOP and the difference in ECD between the affected eye and the fellow eye. Conclusions MMP-3 level is elevated in the aqueous humor of PSS patients, and it may play an important role in the pathogenesis of PSS.
- 14 August 2024
- Published by Taylor & Francis in Current Eye Research
- Vol. 49 (11) , 1180-1183
Expression of Matrix Metalloproteinase-3 in the Aqueous Humor of Patients with Posner-Schlossman Syndrome
Purpose To explore the expression of matrix metalloproteinase-3 (MMP-3) in the aqueous humor of patients with Posner-Schlossman syndrome (PSS), and the association between MMP-3 and PSS. Methods Peripheral blood and aqueous humor were routinely collected from 29 patients with PSS (PSS group) and 30 patients with age-related-cataract (ARC) (control group). The content of MMP-3 in serum and aqueous humor was measured by immunoturbidimetry. The correlation between MMP-3 and ophthalmic examination results were verified by Spearman's correlation analysis. Results The MMP-3 level in the aqueous humor of the PSS group was (25.86 +/- 13.4)ng/ml, significantly higher than that in the control group (3.9 +/- 2.7)ng/ml(p < 0.001), while there was no significant difference in serum MMP-3 level between the two groups (p = 0.125). The endothelial cell density (ECD) in the aqueous humor of the PSS group was (2078 +/- 440) cell/mm2, intraocular pressure (IOP) in the aqueous humor of the PSS group was (33 +/- 12) mmHg. The correlation analysis of aqueous humor MMP-3 and various ophthalmic examination results showed that aqueous humor MMP-3 had a moderate correlation with IOP and the difference in ECD between the affected eye and the fellow eye. Conclusions MMP-3 level is elevated in the aqueous humor of PSS patients, and it may play an important role in the pathogenesis of PSS.
- Open Access
- 14 August 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11, 1196202
The occurrence of acute primary angle closure triggered, aggravated, and accelerated by COVID-19 infection: retrospective observational study
Introduction: The aim of this study is to demonstrate the relevance of primary acute angle closure (APAC) and COVID-19 infection, compare the demographic features and manifestations between COVID-19 positive and negative patients with APAC, and infer the underlying mechanism.Methods: This study is based on all patients diagnosed with APAC at the glaucoma center of Eye, Ear, Nose and Throat Hospital of Fudan University (Fenyang road center) from 15th December 2022 to 11th January 2023. Totally 171 APAC cases were categorized into COVID-19 positive and negative group. Demographic features and final treatment level of the patients were compared between the two groups. Clinical manifestations, intraocular pressure, and anterior chamber configuration were also compared between the two groups.Results: In the COVID-19 positive group, the number of cases with APAC onset spiked in 22nd December 2022, which coincided with the spike of COVID-19 antigen positive people. Compared to the COVID-19 negative group, COVID-19 positive APAC patients were younger with a lower percentage of APAC history. Additionally, more eyes of COVID-19 positive APAC patients showed keratic precipitates. COVID-19 positive eyes had significantly larger anterior chamber depth with a more dilated pupil. Therefore, COVID-19 infection could probably act as a triggering factor of APACDiscussion: The onset of APAC might be accelerated by COVID-19 infection for patients with younger age and milder anatomical configuration. Additionally, COVID-19 related APAC cases might have a more abrupt and fierce onset. Ophthalmic emergent services should not be neglected during the epidemic period.
- 14 August 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11, 1196202
Open AccessThe occurrence of acute primary angle closure triggered, aggravated, and accelerated by COVID-19 infection: retrospective observational study
Introduction: The aim of this study is to demonstrate the relevance of primary acute angle closure (APAC) and COVID-19 infection, compare the demographic features and manifestations between COVID-19 positive and negative patients with APAC, and infer the underlying mechanism.Methods: This study is based on all patients diagnosed with APAC at the glaucoma center of Eye, Ear, Nose and Throat Hospital of Fudan University (Fenyang road center) from 15th December 2022 to 11th January 2023. Totally 171 APAC cases were categorized into COVID-19 positive and negative group. Demographic features and final treatment level of the patients were compared between the two groups. Clinical manifestations, intraocular pressure, and anterior chamber configuration were also compared between the two groups.Results: In the COVID-19 positive group, the number of cases with APAC onset spiked in 22nd December 2022, which coincided with the spike of COVID-19 antigen positive people. Compared to the COVID-19 negative group, COVID-19 positive APAC patients were younger with a lower percentage of APAC history. Additionally, more eyes of COVID-19 positive APAC patients showed keratic precipitates. COVID-19 positive eyes had significantly larger anterior chamber depth with a more dilated pupil. Therefore, COVID-19 infection could probably act as a triggering factor of APACDiscussion: The onset of APAC might be accelerated by COVID-19 infection for patients with younger age and milder anatomical configuration. Additionally, COVID-19 related APAC cases might have a more abrupt and fierce onset. Ophthalmic emergent services should not be neglected during the epidemic period.
- 3 August 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 258, 145-157
Outcomes of Filtering Surgery Versus Clear Lens Extraction in Young Patients With Angle-Closure Glaucoma
- 3 August 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 258, 145-157
Outcomes of Filtering Surgery Versus Clear Lens Extraction in Young Patients With Angle-Closure Glaucoma
- Open Access
- 13 January 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 10, 1051378
Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China
Introduction: This retrospective study aims to present the characteristics of Posner-Schlossman syndrome (PSS) relapse following inactivated COVID-19 vaccination.Methods: From 2020 to 2022, 12 out of 106 PSS patients undergoing relapses after any dose of inactivated COVID-19 vaccines were enrolled. Medical histories, information on the vaccination and systemic adverse events were collected. Patients were treated with corticosteroids, intraocular pressure (IOP)-lowering drugs and systemic immunosuppressive agents (if needed). Daily regimen and release course were noted.Results: The recurrence rate after vaccination was 11.32% (12/106, 95% CI: 5.29%–17.35%) among 106 PSS patients we surveyed. All the 12 patients were inoculated with inactivated COVID-19 vaccines developed by Sinopharm, China. The mean time of relapse was 5.27 ± 3.72 days (range: 1–13 days, median: 4 days). Higher IOP and more keratic precipitates (KPs) were seen in the relapse following vaccination (33.55 ± 12.99 mmHg, 91.67% had KPs compared to 25.38 ± 3.80 mmHg, 33.33% had KPs in previous relapse, P = 0.009). The mean release course was 30.71 ± 34.74 days for the relapse following vaccination and 7.33 ± 6.51 days for previous relapses. The attack frequency before and after vaccination was 3.56 ± 2.07 and 9.11 ± 7.34 times per year (P = 0.044). Higher daily doses of corticosteroids, IOP-lowering drugs and ganciclovir were needed to maintain stable course, though the difference did not reach statistical significance.Discussion: More frequent relapses and harder control of IOP were found in PSS relapse following COVID-19 vaccination. Ophthalmologists need to be aware of the group vulnerability and take precautions, though the pathogenesis is still under investigation.
- 13 January 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 10, 1051378
Open AccessPosner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China
Introduction: This retrospective study aims to present the characteristics of Posner-Schlossman syndrome (PSS) relapse following inactivated COVID-19 vaccination.Methods: From 2020 to 2022, 12 out of 106 PSS patients undergoing relapses after any dose of inactivated COVID-19 vaccines were enrolled. Medical histories, information on the vaccination and systemic adverse events were collected. Patients were treated with corticosteroids, intraocular pressure (IOP)-lowering drugs and systemic immunosuppressive agents (if needed). Daily regimen and release course were noted.Results: The recurrence rate after vaccination was 11.32% (12/106, 95% CI: 5.29%–17.35%) among 106 PSS patients we surveyed. All the 12 patients were inoculated with inactivated COVID-19 vaccines developed by Sinopharm, China. The mean time of relapse was 5.27 ± 3.72 days (range: 1–13 days, median: 4 days). Higher IOP and more keratic precipitates (KPs) were seen in the relapse following vaccination (33.55 ± 12.99 mmHg, 91.67% had KPs compared to 25.38 ± 3.80 mmHg, 33.33% had KPs in previous relapse, P = 0.009). The mean release course was 30.71 ± 34.74 days for the relapse following vaccination and 7.33 ± 6.51 days for previous relapses. The attack frequency before and after vaccination was 3.56 ± 2.07 and 9.11 ± 7.34 times per year (P = 0.044). Higher daily doses of corticosteroids, IOP-lowering drugs and ganciclovir were needed to maintain stable course, though the difference did not reach statistical significance.Discussion: More frequent relapses and harder control of IOP were found in PSS relapse following COVID-19 vaccination. Ophthalmologists need to be aware of the group vulnerability and take precautions, though the pathogenesis is still under investigation.